Evidence map›Paper›PMID 33844024›Full record

ArticleGenetics2021

Compensation for the absence of the catalytically active half of DNA polymerase ε in yeast by positively selected mutations in CDC28.

Elena I Stepchenkova, Anna S Zhuk, Jian Cui, Elena R Tarakhovskaya, Stephanie R Barbari, Polina V Shcherbakova, Dmitrii E Polev, Roman Fedorov, Eugenia Poliakov, Igor B Rogozin and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Polymorphism ofInternational journal of molecular sciences · 2023
    Article
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Elena I StepchenkovaLaboratory of Mutagenesis and Genetic Toxicology, Vavilov Institute of General Genetics, Saint-Petersburg Branch, Russian Academy of Sciences, Saint-Petersburg 199034, Russia.
Anna S ZhukITMO University, Saint-Petersburg 191002, Russia.
Jian CuiEppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Elena R TarakhovskayaLaboratory of Mutagenesis and Genetic Toxicology, Vavilov Institute of General Genetics, Saint-Petersburg Branch, Russian Academy of Sciences, Saint-Petersburg 199034, Russia.
Stephanie R BarbariEppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Polina V ShcherbakovaEppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Dmitrii E PolevResearch Resource Center "Biobank," Research Park, Saint-Petersburg State University, Saint-Petersburg 198504, Russia.
Roman FedorovDepartment of Mathematics, University of Pittsburgh, PA 15213, USA.
Eugenia PoliakovLaboratory of Retinal Cell and Molecular Biology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Igor B RogozinNational Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD 20894, USA.
Artem G LadaDepartment of Microbiology and Molecular Genetics, University of California Davis, Davis, CA 92697, USA.
Youri I PavlovDepartment of Genetics and Biotechnology, Saint-Petersburg State University, Saint-Petersburg 199034, Russia.ORCID 0000-0003-1179-5796
St Petersburg University · RUUniversity of Nebraska Medical Center · USNational Institutes of Health · USITMO University · RUUniversity of California, Davis · USUniversity of Pittsburgh · US

Funding

UNMC Structural Biology CoreP20GM103427 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI PAUL L SORGEN · 2012 to 2026
$59.2M
UNMC/EPPLEY CANCER CENTER SUPPORT GRANTP30CA036727 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Joann B. Sweasy · 1985 to 2026
$55.0M
CHEMICAL CARCINOGENESIS &CANCER BIOLOGYT32CA009476 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Jennifer D. Black · 1988 to 2026
$6.2M
UNMC Histology/Imaging and Creighton University Imaging Core FacilityP30GM110768 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI SMITH, SHELLEY D · 2014 to 2018
$5.1M
Research Pilot Project ProgramP30GM106397 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI JOHNSON, KEITH R · 2013 to 2017
$4.9M
Translesion Synthesis DNA Polymerases and Genome InstabilityR01ES015869 · NIEHS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI SHCHERBAKOVA, POLINA V · 2009 to 2023
$4.7M
Mechanisms of Genome Instability in Tumors with DNA Polymerase Epsilon MutationsR01CA239688 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI SHCHERBAKOVA, POLINA V · 2020 to 2024
$2.3M
NCI NIH HHS P30 CA036727NCI NIH HHS R01 CA239688NCI NIH HHS T32 CA009476NIEHS NIH HHS R01 ES015869NIGMS NIH HHS P20 GM103427NIGMS NIH HHS P30 GM106397NIGMS NIH HHS P30 GM110768
6 · The paper itself

Abstract

Current eukaryotic replication models postulate that leading and lagging DNA strands are replicated predominantly by dedicated DNA polymerases. The catalytic subunit of the leading strand DNA polymerase ε, Pol2, consists of two halves made of two different ancestral B-family DNA polymerases. Counterintuitively, the catalytically active N-terminal half is dispensable, while the inactive C-terminal part is required for viability. Despite extensive studies of yeast Saccharomyces cerevisiae strains lacking the active N-terminal half, it is still unclear how these strains survive and recover. We designed a robust method for constructing mutants with only the C-terminal part of Pol2. Strains without the active polymerase part show severe growth defects, sensitivity to replication inhibitors, chromosomal instability, and elevated spontaneous mutagenesis. Intriguingly, the slow-growing mutant strains rapidly accumulate fast-growing clones. Analysis of genomic DNA sequences of these clones revealed that the adaptation to the loss of the catalytic N-terminal part of Pol2 occurs by a positive selection of mutants with improved growth. Elevated mutation rates help generate sufficient numbers of these variants. Single nucleotide changes in the cell cycle-dependent kinase gene, CDC28, improve the growth of strains lacking the N-terminal part of Pol2, and rescue their sensitivity to replication inhibitors and, in parallel, lower mutation rates. Our study predicts that changes in mammalian homologs of cyclin-dependent kinases may contribute to cellular responses to the leading strand polymerase defects.

Indexed as

DNA ReplicationCDC28 Protein Kinase, S cerevisiaeDNA, FungalDNA Polymerase IIGenome, FungalMutagenesisMutation RatePolymorphism, Single NucleotideSaccharomyces cerevisiaeSelection, GeneticCDC28 Protein Kinase, S cerevisiaeDNA, FungalDNA Polymerase IICDC28cyclin-dependent kinaseDNA polymerase εDNA replicationillegitimate matingleading strandmutation ratesyeast

Identifiers

PMID33844024
PMCPMC8225352
OpenAlexW3152560410

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.